Cargando…

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer

The CD13 inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The proteasome inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jian, Sun, Simin, Liu, Jinyu, Zhang, Liang, Guo, Di, Zhang, Naixin, Zhao, Jun, Kong, Dexin, Xu, Tongqiang, Wang, Xuejian, Xu, Wenfang, Li, Xiaoyang, Jiang, Yuqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489073/ https://www.ncbi.nlm.nih.gov/pubmed/37687169 http://dx.doi.org/10.3390/molecules28176343

Ejemplares similares

Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells
por: Guo, Qie, et al.
Publicado: (2017)

A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma
por: YAMASHITA, MASAFUMI, et al.
Publicado: (2016)

Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer
por: Tsukamoto, Hirohisa, et al.
Publicado: (2008)

Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer
por: Shi, Yunyan, et al.
Publicado: (2023)

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity
por: Li, Xiaoyang, et al.
Publicado: (2014)

Inhibition of Tumor Cell Invasion by Ubenimex (Bestatin) in vitro
por: Saiki, Ikuo, et al.
Publicado: (1989)

Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway
por: Liu, Xuehui, et al.
Publicado: (2021)

Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis
por: Guo, Qie, et al.
Publicado: (2019)

Role of ubenimex as an anticancer drug and its synergistic effect with Akt inhibitor in human A375 and A2058 cells
por: Wang, Xiaoqing, et al.
Publicado: (2018)

Ubenimex Activates the E‐Cadherin‐mediated Adhesion of a Breast Cancer Cell Line YMB‐S
por: Fujioka, Seiji, et al.
Publicado: (1995)

Ubenimex induces apoptotic and autophagic cell death in rat GH3 and MMQ cells through the ROS/ERK pathway
por: Wang, Yanjun, et al.
Publicado: (2019)

CD13 downregulation mediated by ubenimex inhibits autophagy to overcome 5-FU resistance by disturbing the EMP3/FAK/NF-κB pathway in gastric cancer cells
por: Xiu, Ting, et al.
Publicado: (2022)

Ubenimex, an APN inhibitor, could serve as an anti-tumor drug in RT112 and 5637 cells by operating in an Akt-associated manner
por: Wang, Xiaoqing, et al.
Publicado: (2018)

Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells
por: Han, Liping, et al.
Publicado: (2017)

Autophagy flux inhibition, G2/M cell cycle arrest and apoptosis induction by ubenimex in glioma cell lines
por: Han, Liping, et al.
Publicado: (2017)

Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors
por: Yang, Kanghui, et al.
Publicado: (2009)

Ubenimex Reverses MDR in Gastric Cancer Cells by Activating Caspase-3-Mediated Apoptosis and Suppressing the Expression of Membrane Transport Proteins
por: Guo, Qie, et al.
Publicado: (2019)

Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway
por: Chen, Quan, et al.
Publicado: (2022)

Design, synthesis and primary activity evaluation of l-arginine derivatives as amino-peptidase N/CD13 inhibitors
por: Mou, Jiajia, et al.
Publicado: (2009)

Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism
por: Liu, Shuai, et al.
Publicado: (2016)

Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P‐glycoprotein expression level in non‐small lung cancer
por: Wan, Jun, et al.
Publicado: (2020)

Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor
por: Shao, Li-jun, et al.
Publicado: (2022)

Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding
por: Kikuchi, Jiro, et al.
Publicado: (2013)

Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo
por: Tandon, Vasudha, et al.
Publicado: (2022)

Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms
por: Kong, Dexin, et al.
Publicado: (2011)

Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma
por: Estrada, Filipe G. A., et al.
Publicado: (2021)

Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview
por: Guedes, Romina A., et al.
Publicado: (2016)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
por: Zhao, Wennan, et al.
Publicado: (2017)

An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool
por: Verkerk, Tamara, et al.
Publicado: (2022)

Structural basis for the recognition of K48-linked Ub chain by proteasomal receptor Rpn13
por: Liu, Zhu, et al.
Publicado: (2019)

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022)

Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
por: Forster, Michael, et al.
Publicado: (2020)

CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents
por: Zhang, Jian, et al.
Publicado: (2018)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

Interactions of SARS Coronavirus Nucleocapsid Protein with the host cell proteasome subunit p42
por: Wang, Qin, et al.
Publicado: (2010)

Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)
por: Koester, Dennis C., et al.
Publicado: (2022)

The role of the proteasome in the generation of MHC class I ligands and immune responses
por: Sijts, E. J. A. M., et al.
Publicado: (2011)

Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer
por: Lü, Lingshuang, et al.
Publicado: (2017)

Developing a class of dual atom materials for multifunctional catalytic reactions
por: Wang, Xingkun, et al.
Publicado: (2023)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7dujggf6ou2se3a3s0hqsvit73